Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results.
Hughes TP, Leber B, Cervantes F, Spector N, Pasquini R, Clementino NCD, Schwarer AP, Dorlhiac-Llacer PE, Mahon FX, Rea D, Guerci-Bresler A, Kamel-Reid S, Bendit I, Acharya S, Glynos T, Dalal D, Branford S, Lipton JH.
Hughes TP, et al. Among authors: acharya s.
Leukemia. 2017 Nov;31(11):2529-2531. doi: 10.1038/leu.2017.247. Epub 2017 Aug 3.
Leukemia. 2017.
PMID: 28862704
Free PMC article.
Clinical Trial.
No abstract available.